8-K: CeriBell Reports Strong 2025 Revenue, Key FDA Clearances

CeriBell, Inc. announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and critical FDA regulatory milestones.

Summary

• Total revenue for the fourth quarter of 2025 reached $24.8 million, a 34% increase compared to $18.5 million in Q4 2024.
• Full year 2025 total revenue was $89.1 million, marking a 36% increase from $65.4 million in 2024.
• Gross margin remained strong at 87% for Q4 2025 and 88% for the full year 2025.
• Net loss for Q4 2025 was $13.5 million ($0.36 per share), compared to $12.6 million ($0.40 per share) in Q4 2024.
• Full year 2025 net loss was $53.4 million ($1.46 per share), compared to $40.5 million ($3.39 per share) in 2024.
• The company ended 2025 with 647 total active accounts.
• CeriBell received FDA 510(k) clearance for a continuous monitoring solution for delirium and for the Clarity algorithm for neonates, making it the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults.
• FDA Breakthrough Device Designation was granted for a first-in-class large vessel occlusion (LVO) stroke detection and monitoring solution.
• Cash, cash equivalents, and marketable securities totaled $159.3 million as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by exceptional revenue growth, significant regulatory breakthroughs that unlock substantial new market opportunities, and an improved net loss per share, despite increased operating expenses reflecting strategic investments for future expansion.

Positives

• Achieved substantial revenue growth of 34% in Q4 2025 and 36% for the full year 2025, indicating strong market adoption.
• Maintained high gross margins of 87% in Q4 2025 and 88% for the full year, demonstrating efficient cost management relative to revenue.
• Expanded active account base to 647, reflecting successful market penetration and customer acquisition.
• Secured FDA 510(k) clearance for a continuous monitoring solution for delirium, broadening product utility.
• Received FDA 510(k) clearance for the Clarity algorithm for neonates, establishing a unique market position as the first and only such solution for pre-term neonates through adults.
• Obtained FDA Breakthrough Device Designation for an LVO stroke detection and monitoring solution, highlighting innovative technology and potential for expedited review.
• Management believes these regulatory milestones unlock incremental market opportunities exceeding $1.5 billion.
• Net loss per share improved significantly for the full year 2025 to $1.46 from $3.39 in 2024, and slightly for Q4 2025 to $0.36 from $0.40 in Q4 2024, despite increased absolute net loss, indicating better performance relative to the increased share count.

Negatives

• Net loss increased to $13.5 million in Q4 2025 from $12.6 million in Q4 2024, and to $53.4 million for the full year 2025 from $40.5 million in 2024.
• Operating expenses rose significantly by 24% in Q4 2025 to $36.2 million and by 42% for the full year 2025 to $136.7 million, primarily due to investments in commercial organization, increased headcount, legal expenses, and public company operating costs.
• Cash, cash equivalents, and marketable securities decreased to $159.3 million as of December 31, 2025, from $194.37 million in cash and cash equivalents as of December 31, 2024, indicating a significant cash burn.

Risks

• Limited operating history and a history of net losses.
• Ability to successfully achieve substantial market acceptance and adoption of products.
• Competitive pressures within the medical technology industry.
• Ability to adapt manufacturing and production capacities to evolving demand and trends.
• Dependence on manufacturing a substantial number of product components and their assembly in China and Vietnam.
• Potential for product defects or complaints and related liability.
• Complexity, timing, expense, and outcomes of clinical studies, legal matters, and regulatory compliance.
• Ability to obtain and maintain adequate coverage and reimbursement levels for products.
• Ability to comply with changing laws and regulatory requirements and resulting costs.
• Dependence on a limited number of suppliers.

Future Outlook

CeriBell expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29% over the company's prior year revenue.

Management Comments

• Co-founder and CEO Jane Chao, Ph.D., stated that 2025 was a milestone year for Ceribell, marked by accelerated adoption, broadened age range for their seizure detection algorithm, and critical regulatory milestones.
• Chao highlighted that these accomplishments unlock incremental market opportunities believed to exceed $1.5 billion.
• Management believes these achievements position the company well for continued growth and to advance its long-term vision of making EEG a new vital sign.

Industry Context

StockSavvy.ai notes that CeriBell's strong revenue growth and significant regulatory achievements, particularly the FDA clearances for neonatal seizure detection and delirium monitoring, and Breakthrough Device Designation for LVO stroke, position it as a key innovator in the acute-care neurological diagnostics market. These advancements expand its addressable market and strengthen its competitive moat against traditional EEG providers and emerging med-tech companies, aligning with a broader industry trend towards point-of-care, AI-powered diagnostic solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. However, the FDA Breakthrough Device Designation for LVO stroke detection suggests the technology is considered novel and potentially superior to existing methods for this critical condition, which is a high bar in medical device innovation.
• Being the 'first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults' for the Clarity algorithm sets a new standard for comprehensive age-range coverage in EEG diagnostics, differentiating CeriBell from competitors who may have more limited indications.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation due to strong revenue growth, expanded market opportunities from regulatory clearances, and improved per-share loss, though continued cash burn and unprofitability present ongoing risks.
• Customers (healthcare providers): Benefit from enhanced diagnostic capabilities with new FDA-cleared solutions for delirium monitoring, neonatal seizure detection, and potential LVO stroke detection, improving patient care in acute settings.
• Employees: Increased headcount and investments in the commercial organization suggest job growth and stability within the company.
• Creditors: The decrease in cash and cash equivalents, despite marketable securities, indicates a high burn rate, which could be a consideration for future credit assessments.

Next Steps

• CeriBell will host a conference call on February 24, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2025 financial results.

Key Dates

Recommendation

The company demonstrates exceptional top-line growth, significant regulatory achievements that unlock substantial new market opportunities (exceeding $1.5 billion), and a strong competitive position with 'first-of-its-kind' and 'first and only' FDA clearances. While the company is still unprofitable and has a high cash burn, these are typical characteristics of a high-growth medical technology company investing heavily in market expansion and R&D. The improved net loss per share indicates increasing efficiency. For investors with a long-term horizon and a tolerance for growth-stage risks, the strategic advancements and market potential make this a compelling 'strong buy'.

Keywords

Medical Technology, EEG, Neurological Conditions, FDA Clearance, Seizure Detection, Delirium Monitoring, Stroke Detection, Financial Results, Revenue Growth, Net Loss, Q4 2025, Full Year 2025, CBLL